# Chemotherapy-induced cardiotoxicity and mitigation

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/chemotherapy-induced-cardiotoxicity-and-mitigation/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the cardiotoxic effects of various cancer treatments, particularly anthracyclines and related drugs like doxorubicin and trastuzumab. It explores the molecular mechanisms, pharmacologic developments, early detection, prevention, and management of cardiotoxicity in cancer patients. The papers also discuss the long-term cardiovascular complications and survival outcomes in individuals undergoing these treatments. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11535 |
| Works | 142 |

## Topic papers all

Showing 15 of 142.

- [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://scholariq.org/papers/2022-esc-guidelines-on-cardio-oncology-developed-in-collaboration-with-the-2/)
- [Doxorubicin pathways](https://scholariq.org/papers/doxorubicin-pathways/)
- [Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience](https://scholariq.org/papers/cardiac-dysfunction-in-the-trastuzumab-clinical-trials-experience/)
- [Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations](https://scholariq.org/papers/management-of-cardiac-disease-in-cancer-patients-throughout-oncological/)
- [Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data](https://scholariq.org/papers/rates-of-initial-and-recurrent-thromboembolic-disease-among-patients-with/)
- [American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer](https://scholariq.org/papers/american-society-of-hematology-2021-guidelines-for-management-of-venous/)
- [Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab](https://scholariq.org/papers/assessment-of-echocardiography-and-biomarkers-for-the-extended-prediction-of/)
- [Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society](https://scholariq.org/papers/baseline-cardiovascular-risk-assessment-in-cancer-patients-scheduled-to-receive/)
- [Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials](https://scholariq.org/papers/efficacy-and-safety-of-statin-therapy-in-older-people-a-meta-analysis-of/)
- [Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion](https://scholariq.org/papers/reduction-of-doxorubicin-cardiotoxicity-by-prolonged-continuous-intravenous/)
- [Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity](https://scholariq.org/papers/human-induced-pluripotent-stem-cell-derived-cardiomyocytes-recapitulate-the/)
- [Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction](https://scholariq.org/papers/contrast-induced-nephropathy-in-patients-undergoing-primary-angioplasty-for/)
- [Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia](https://scholariq.org/papers/adverse-cardiac-effects-of-cancer-therapies-cardiotoxicity-and-arrhythmia/)
- [Development and Validation of a Heart Atlas to Study Cardiac Exposure to Radiation Following Treatment for Breast Cancer](https://scholariq.org/papers/development-and-validation-of-a-heart-atlas-to-study-cardiac-exposure-to/)
- [Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer](https://scholariq.org/papers/rivaroxaban-for-thromboprophylaxis-in-high-risk-ambulatory-patients-with-cancer/)

## Topic primary papers

Showing 15 of 71.

- [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://scholariq.org/papers/2022-esc-guidelines-on-cardio-oncology-developed-in-collaboration-with-the-2/)
- [Doxorubicin pathways](https://scholariq.org/papers/doxorubicin-pathways/)
- [Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience](https://scholariq.org/papers/cardiac-dysfunction-in-the-trastuzumab-clinical-trials-experience/)
- [Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations](https://scholariq.org/papers/management-of-cardiac-disease-in-cancer-patients-throughout-oncological/)
- [Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab](https://scholariq.org/papers/assessment-of-echocardiography-and-biomarkers-for-the-extended-prediction-of/)
- [Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society](https://scholariq.org/papers/baseline-cardiovascular-risk-assessment-in-cancer-patients-scheduled-to-receive/)
- [Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion](https://scholariq.org/papers/reduction-of-doxorubicin-cardiotoxicity-by-prolonged-continuous-intravenous/)
- [Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity](https://scholariq.org/papers/human-induced-pluripotent-stem-cell-derived-cardiomyocytes-recapitulate-the/)
- [Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia](https://scholariq.org/papers/adverse-cardiac-effects-of-cancer-therapies-cardiotoxicity-and-arrhythmia/)
- [Development and Validation of a Heart Atlas to Study Cardiac Exposure to Radiation Following Treatment for Breast Cancer](https://scholariq.org/papers/development-and-validation-of-a-heart-atlas-to-study-cardiac-exposure-to/)
- [Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol](https://scholariq.org/papers/prevention-of-cardiac-dysfunction-during-adjuvant-breast-cancer-therapy-prada-a/)
- [Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients](https://scholariq.org/papers/early-detection-and-prediction-of-cardiotoxicity-in-chemotherapy-treated/)
- [Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity](https://scholariq.org/papers/mitochondria-dependent-ferroptosis-plays-a-pivotal-role-in-doxorubicin/)
- [Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement](https://scholariq.org/papers/defining-cardiovascular-toxicities-of-cancer-therapies-an-international-cardio/)
- [Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab](https://scholariq.org/papers/early-increases-in-multiple-biomarkers-predict-subsequent-cardiotoxicity-in/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.